Sanofi places new $1.9B bet even as its last sours; Sam Waksal's new biotech ideas; Cell therapy time for Roche; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As if by some cosmic karma force, short weeks always have an extra load of big news — as if to compensate. If you find this report helpful in recapping it all, please do share it with your colleagues and friends. Our inboxes are always open if you have any feedback or suggestions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.